Trial Profile
The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti CD19/CD20 CAR T cell therapy Shanghai Longyao Biotechnology (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- 10 Jul 2018 New trial record